RecruitingPhase 2Drug trialA Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell LymphomaThis study aims to evaluate whether maintenance therapy with Zanubrutinib monotherapy could improve the 2-year progression free survival (PFS) of patients with mantle cell lymphoma who had remission after first-line immunochemotherapy